Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Nov 15;59(10):1364-74.
doi: 10.1093/cid/ciu619. Epub 2014 Aug 5.

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis

Mayara L Bastos, Hamidah Hussain, Karin Weyer, Lourdes Garcia-Garcia, Vaira Leimane, Chi Chiu Leung, Masahiro Narita, Jose M Penã, Alfredo Ponce-de-Leon, Kwonjune J Seung, Karen Shean, José Sifuentes-Osornio, Martie Van der Walt, Tjip S Van der Werf, Wing Wai Yew, Dick Menzies; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB
Collaborators
Meta-Analysis

Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis

Mayara L Bastos et al. Clin Infect Dis. .

Abstract

Background: Individualized treatment for multidrug-resistant (MDR) tuberculosis and extensively drug-resistant (XDR) tuberculosis depends upon reliable and valid drug susceptibility testing (DST) for pyrazinamide, ethambutol, and second-line tuberculosis drugs. However, the reliability of these tests is uncertain, due to unresolved methodological issues. We estimated the association of DST results for pyrazinamide, ethambutol, and second-line drugs with treatment outcomes in patients with MDR tuberculosis and XDR tuberculosis.

Methods: We conducted an analysis of individual patient data assembled from 31 previously published cohort studies of patients with MDR and XDR tuberculosis. We used data on patients' clinical characteristics including DST results, treatment received, outcomes, and laboratory methods in each center.

Results: DST methods and treatment regimens used in different centers varied considerably. Among 8955 analyzed patients, in vitro susceptibility to individual drugs was consistently and significantly associated with higher odds of treatment success (compared with resistance to the drug), if that drug was used in the treatment regimen. Various adjusted and sensitivity analyses suggest that this was not explained by confounding. The adjusted odds of treatment success for ethambutol, pyrazinamide, and the group 4 drugs ranged from 1.7 to 2.3, whereas for second-line injectables and fluoroquinolones, odds ranged from 2.4 to 4.6.

Conclusions: DST for ethambutol, pyrazinamide, and second-line tuberculosis drugs appears to provide clinically useful information to guide selection of treatment regimens for MDR and XDR tuberculosis.

Keywords: drug susceptibility test; meta-analysis; multidrug resistant; treatment outcomes; tuberculosis.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Flowchart of study selection. Abbreviations: MDR-TB, multidrug-resistant tuberculosis; XDR-TB, extensively drug-resistant tuberculosis.
See this image and copyright information in PMC

Comment in

References

    1. World Health Organization. Global tuberculosis report. 2013. Available at: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656_eng.pdf . Accessed 22 October 2013.
    1. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621–9. - PubMed
    1. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis—2011 update. Available at: http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf . Accessed 22 October 2013. - PubMed
    1. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. 2008. Available at: http://whqlibdoc.who.int/hq/2008/WHO_HTM_TB_2008.392_eng.pdf . Accessed 22 October 2013. - PubMed
    1. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25:564–9. - PubMed

Publication types

Substances